Clinical, laboratory and genetic features of Erdheim-Chester disease patients: analysis of a retrospective cohort of two reference centers in Latin America
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Citação
HEMATOLOGY, v.27, n.1, p.65-69, 2022
Resumo
Objectives and Methods: Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm with a heterogeneous clinical course, ranging from localized and asymptomatic bone lesions to a multisystem disease, causing significant morbidity and mortality. There are few cohorts published, mainly from North America and Europe. We retrospectively collected clinical data on sixteen biopsy-proven ECD patients diagnosed and treated at two Brazilian reference centres for histiocytic disorders from January 2006 to February 2020. Results: Median time from onset of symptoms to diagnosis was 13 months (0.1-142). The main organ involved in ECD was bone (75%) and also 75% of the patients presented involvement of more than one organ, characterizing a multi-organic form. BRAF status was available in 81.2% of patients and BRAF V600E mutation was detected by Sanger sequencing in only 18.8%, which can be explained by the low sensitivity of this technique. All patients were treated due to symptomatic disease and a median of two lines (range: 1-7) of therapy were needed. The most common first-line therapy used was alpha-interferon (75%). The median progression-free survival was 7.5 months, and the median OS was not reached. Discussion and Conclusion: In the largest Latin American cohort of patients with ECD reported to date, we observed findings which resemble demographic characteristics, sites of involvement and treatment choices reported by other groups. The outcomes may be better with target therapies such as BRAF and MEK inhibitors in patients with mutation and with the adoption of recently published consensus recommendations for the management of ECD patients.
Palavras-chave
Erdheim-Chester disease, BRAF mutation, Latin America patients
Referências
- Arnaud L, 2011, BLOOD, V117, P2778, DOI 10.1182/blood-2010-06-294108
- Cao XX, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-018-0988-y
- Cao XX, 2016, ANN HEMATOL, V95, P745, DOI 10.1007/s00277-016-2606-1
- Cohen-Aubart F, 2018, AM J HEMATOL, V93, pE114, DOI 10.1002/ajh.25055
- Diamond EL, 2018, JAMA ONCOL, V4, P384, DOI 10.1001/jamaoncol.2017.5029
- Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01690636, 10.1182/blood-2016-01-690636]
- Estrada-Veras JI, 2017, BLOOD ADV, V1, P357, DOI 10.1182/bloodadvances.2016001784
- Goyal G, 2020, BLOOD, V135, P1929, DOI 10.1182/blood.2019003507
- Haroche J, 2020, BLOOD, V135, P1311, DOI 10.1182/blood.2019002766
- Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140
- Melloul S, 2019, HAEMATOLOGICA, V104, pE97, DOI 10.3324/haematol.2018.201194
- Roverano S, 2016, CLIN RHEUMATOL, V35, P1625, DOI 10.1007/s10067-016-3269-y
- Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569
- Toya T, 2018, HAEMATOLOGICA, V103, P1815, DOI 10.3324/haematol.2018.190728